These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37736191)

  • 1. Molecular Design of Cyclic Peptides with Cell Membrane Permeability and Development of MDMX-p53 Inhibitor.
    Mizuno-Kaneko M; Hashimoto I; Miyahara K; Kochi M; Ohashi N; Tsumura K; Suzuki K; Tamura T
    ACS Med Chem Lett; 2023 Sep; 14(9):1174-1178. PubMed ID: 37736191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational modeling of cyclic peptide inhibitor-MDM2/MDMX binding through global docking and Gaussian accelerated molecular dynamics simulations.
    Wang YT; Cheng TL
    J Biomol Struct Dyn; 2021 Jul; 39(11):4005-4014. PubMed ID: 32448094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting intracellular protein-protein interactions with cell-permeable cyclic peptides.
    Qian Z; Dougherty PG; Pei D
    Curr Opin Chem Biol; 2017 Jun; 38():80-86. PubMed ID: 28388463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angler Peptides: Macrocyclic Conjugates Inhibit p53:MDM2/X Interactions and Activate Apoptosis in Cancer Cells.
    Philippe GJ; Mittermeier A; Lawrence N; Huang YH; Condon ND; Loewer A; Craik DJ; Henriques ST
    ACS Chem Biol; 2021 Feb; 16(2):414-428. PubMed ID: 33533253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incorporation of Putative Helix-Breaking Amino Acids in the Design of Novel Stapled Peptides: Exploring Biophysical and Cellular Permeability Properties.
    Partridge AW; Kaan HYK; Juang YC; Sadruddin A; Lim S; Brown CJ; Ng S; Thean D; Ferrer F; Johannes C; Yuen TY; Kannan S; Aronica P; Tan YS; Pradhan MR; Verma CS; Hochman J; Chen S; Wan H; Ha S; Sherborne B; Lane DP; Sawyer TK
    Molecules; 2019 Jun; 24(12):. PubMed ID: 31226791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
    Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W
    Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions.
    Li C; Pazgier M; Li C; Yuan W; Liu M; Wei G; Lu WY; Lu W
    J Mol Biol; 2010 Apr; 398(2):200-13. PubMed ID: 20226197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leveraging the multivalent p53 peptide-MdmX interaction to guide the improvement of small molecule inhibitors.
    Cheng X; Chen R; Zhou T; Zhang B; Li Z; Gao M; Huang Y; Liu H; Su Z
    Nat Commun; 2022 Feb; 13(1):1087. PubMed ID: 35228542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx.
    Czarna A; Popowicz GM; Pecak A; Wolf S; Dubin G; Holak TA
    Cell Cycle; 2009 Apr; 8(8):1176-84. PubMed ID: 19305137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting intracellular protein-protein interactions with macrocyclic peptides.
    Buyanova M; Pei D
    Trends Pharmacol Sci; 2022 Mar; 43(3):234-248. PubMed ID: 34911657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational studies of difference in binding modes of peptide and non-peptide inhibitors to MDM2/MDMX based on molecular dynamics simulations.
    Chen J; Zhang D; Zhang Y; Li G
    Int J Mol Sci; 2012; 13(2):2176-2195. PubMed ID: 22408446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX.
    Phan J; Li Z; Kasprzak A; Li B; Sebti S; Guida W; Schönbrunn E; Chen J
    J Biol Chem; 2010 Jan; 285(3):2174-83. PubMed ID: 19910468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression.
    Li X; Gohain N; Chen S; Li Y; Zhao X; Li B; Tolbert WD; He W; Pazgier M; Hu H; Lu W
    Acta Pharm Sin B; 2021 Sep; 11(9):2655-2669. PubMed ID: 34589387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Passive Membrane Permeability in Cyclic Peptomer Scaffolds Is Robust to Extensive Variation in Side Chain Functionality and Backbone Geometry.
    Furukawa A; Townsend CE; Schwochert J; Pye CR; Bednarek MA; Lokey RS
    J Med Chem; 2016 Oct; 59(20):9503-9512. PubMed ID: 27690434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding Cell Penetration of Cyclic Peptides.
    Dougherty PG; Sahni A; Pei D
    Chem Rev; 2019 Sep; 119(17):10241-10287. PubMed ID: 31083977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancing Oral Bioavailability of Cyclic RGD Hexa-peptides by the Lipophilic Prodrug Charge Masking Approach: Redirection of Peptide Intestinal Permeability from a Paracellular to Transcellular Pathway.
    Schumacher-Klinger A; Fanous J; Merzbach S; Weinmüller M; Reichart F; Räder AFB; Gitlin-Domagalska A; Gilon C; Kessler H; Hoffman A
    Mol Pharm; 2018 Aug; 15(8):3468-3477. PubMed ID: 29976060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell Membrane Composition Drives Selectivity and Toxicity of Designed Cyclic Helix-Loop-Helix Peptides with Cell Penetrating and Tumor Suppressor Properties.
    Philippe GJ; Gaspar D; Sheng C; Huang YH; Benfield AH; Condon ND; Weidmann J; Lawrence N; Löwer A; Castanho MARB; Craik DJ; Troeira Henriques S
    ACS Chem Biol; 2019 Sep; 14(9):2071-2087. PubMed ID: 31390185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy.
    Chang YS; Graves B; Guerlavais V; Tovar C; Packman K; To KH; Olson KA; Kesavan K; Gangurde P; Mukherjee A; Baker T; Darlak K; Elkin C; Filipovic Z; Qureshi FZ; Cai H; Berry P; Feyfant E; Shi XE; Horstick J; Annis DA; Manning AM; Fotouhi N; Nash H; Vassilev LT; Sawyer TK
    Proc Natl Acad Sci U S A; 2013 Sep; 110(36):E3445-54. PubMed ID: 23946421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies.
    Joseph TL; Madhumalar A; Brown CJ; Lane DP; Verma CS
    Cell Cycle; 2010 Mar; 9(6):1167-81. PubMed ID: 20190571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CycPeptMPDB: A Comprehensive Database of Membrane Permeability of Cyclic Peptides.
    Li J; Yanagisawa K; Sugita M; Fujie T; Ohue M; Akiyama Y
    J Chem Inf Model; 2023 Apr; 63(7):2240-2250. PubMed ID: 36930969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.